Mainz, July 15 2016 – “Uptake of synthetic naked RNA by DCs allows antigen expression and induction of T-cell responses in mice” – TRON scientist shed further insight into the underlying mechanism of RNA uptake, translation and antigen presentation upon intradermal administration of antigen-encoding RNA.
Author Archive | cAdmin
Mainz, Juli 15 2016 – „Forschungsergebnisse werden zu Therapieverfahren”, Interview mit TRONs wisschenschaftlichem Direktor Prof. Dr. Ugur Sahin im SWR.
Mainz, June 30 2016 – “Tissue-resident regulatory T cells”, Dr. Markus Feuerer from the Helmholtz Young Investigator research group “Immune Tolerance” at the German Cancer Research Center (DKFZ), Heidelberg, Germany is visiting TRON. 5 PM, Lecture Hall Building 205, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
Mainz, June 02 2016 Breaking News Publication in the renowned Nature journal describes first example of RNA-Lipoplexes as a novel vaccine class that exploit antiviral immune mechanisms for potent cancer immunotherapy. Read more about the media coverage for TRON’s most recent Nature publication here.
Mainz, June 09 2016 – “Abrogation of the immunosuppressive tumor-microenvironment in Hepatocellular Carcinoma by targeting Treg and co-inhibitory pathways”, Dr. Jaap Kwekkeboom & Dr. Dave Sprengers from Erasmus MC-University Medical Centre, Rotterdam are visiting TRON. 5 PM, Lecture Hall Building 708, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz
Mainz, May 10 – 12 2016 – TRON at CIMT 2016 “Mechanisms of Efficacy in Cancer Immunotherapy” Looking forward to the 2016 Annual Meeting of Cancer Immunotherapy in Mainz. Connect with us at the booth A021 or at any of our posters.
Mainz, April 28 2016 – “Exploiting Natural Killer cells for immunotherapy of cancer”, PD Dr. rer. nat. Adelheid Cerwenka from the German Cancer Research Center (DKFZ) is visiting TRON.
Mainz, April 2016 – Review in CCR Focus “Opportunities and Challenges in Cancer Immunotherapy”: “Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines” TRON and BioNTech scientists have written an overview of the clinical development of individualized neoepitope cancer vaccines, which is published now as CCR Focus Review article in Clinical Cancer Research.
Mainz, April 7 2016 – “Regulation of tumor immunity by macrophage and eosinophils”, Prof. Günter Hämmerling from the German Cancer Research Center (DKFZ) is visiting TRON.
Davos, März 16, 2016 – “Eliciting potent T-cells against individual mutant neoantigens – the mutanome as rich target source for individualized cancer vaccination” Vortrag von Dr. Sebastian Kreiter in der Session “Immune Tolerance” auf dem 10. World Immune Regulation Meeting Davos (CH).
Berlin, Februar 25, 2016 – “Neue Methoden zur Identifizierung von Tumorantigenen als Targets für Tumorvakzine” Vortrag von Mathias Vormehr in der Session “Translationale Onkologie” auf dem 32. Deutschen Krebskongress in Berlin.
Mainz, February 2016TRON/BioNTech in Nature Medicine News Feature: “Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment”TRONs efforts to develop individualized cancer vaccines based on tumor-specific mutations is covered in a recent News Feature published in Nature Medicine.For more information please click the Link below, which will direct you to the Nature